Crinetics Pharmaceuticals Inc (CRNX)

Over the past six months, Crinetics Pharmaceuticals, Inc. stock has been impacted by several events. The FDA approved PALSONIFY in September 2025, leading to a U.S. commercial launch in Q4 2025 that generated $5.4 million in net product revenue. Crinetics reported its fourth quarter and full year 2025 financial results on February 26, 2026, after which CRNX shares declined by 6.0%. In March 2026, Crinetics submitted a Marketing Authorization Application for PALSONIFY in Brazil. Between April 7, 2025, and April 2, 2026, the share price increased by 41.13%. In March 2026, the CEO and CFO sold shares at average prices of $37.37 and $39.67, respectively.

There is no explicit information available indicating significant demand seasonality for Crinetics Pharmaceuticals, Inc.'s products and services. The demand for its therapeutics is likely driven by disease prevalence and treatment needs rather than seasonal fluctuations.

Crinetics Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on discovering, developing, and commercializing novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its major products and pipeline candidates include Paltusotine (PALSONIFY™), an oral SST2 agonist approved for acromegaly and in Phase 3 for carcinoid syndrome; Atumelnant (CRN04894), an investigational oral ACTH antagonist in Phase 2 for congenital adrenal hyperplasia and Cushing's disease; CRN09682, a nonpeptide drug conjugate candidate for SST2-expressing neuroendocrine tumors; and other pipeline programs for endocrine conditions like hyperparathyroidism and diabetes.

Crinetics Pharmaceuticals, Inc. is headquartered in San Diego, California, and has a global pharmaceutical focus. In 2024, it established its first office outside the United States in Zug, Switzerland. The company is expanding internationally, with a Marketing Authorization Application submitted to Brazil's ANVISA for PALSONIFY in March 2026 and an agreement with Sanwa Kagaku Kenkyusho Co., Ltd to develop and commercialize Paltusotine in Japan.

In the past year, Crinetics Pharmaceuticals has maintained a generally positive brand reputation, particularly within the analyst community, while also facing scrutiny regarding profitability. Analysts have given Crinetics a consensus rating of "Moderate Buy" with an average 12-month price target of $76.63. The FDA approval of PALSONIFY and its subsequent successful U.S. commercial launch have significantly bolstered the company's reputation. While the company has shown revenue growth, it remains unprofitable, and losses have increased over the past five years. Zacks Investment Research currently rates Crinetics Pharmaceuticals, Inc. as a "Hold."

Crinetics Pharmaceuticals, Inc. is primarily owned by institutional shareholders, who hold 106.59% of the stock, while insiders own 12.42%, and retail investors hold 0.00%. There are 251 institutional owners and shareholders holding a total of 109,701,523 shares. Major institutional owners include Fmr LLC, Vanguard Group Inc, Wellington Management Group LLP, and BlackRock, Inc. Perceptive Advisors LLC is the largest individual shareholder, owning 7.55% of the company.